Metabolic Health Beyond Weight in the GLP-1 Era
GLP-1s moved the weight number. What moved with it — A1c, ASCVD risk, MASLD, sleep apnea, blood pressure — is where the durable outcomes live. A plain-English map for patients and their clinicians.
The scale is now the least interesting number in the GLP-1 era. What matters — for a durable outcome — is what happened to A1c, ASCVD risk, MASLD, sleep apnea, and blood pressure while the weight came down. This is a plain-English map of the metrics that decide whether the weight loss stuck at year five.
The five numbers that matter more than weight
A1c and fasting glucose: even in patients without diabetes, the trajectory matters. Fasting glucose in the 100–125 range is prediabetes; a GLP-1 that moves you back below 100 is doing durable work.
ASCVD 10-year risk: LDL, non-HDL, and blood pressure are the levers. GLP-1 therapy pulls LDL and BP modestly; the residual gap after 6 months is what a statin and BP med are for.
MASLD/MASH markers: ALT, AST, and a FIB-4 score derived from age, AST/ALT, and platelets. GLP-1s (particularly semaglutide) improve steatosis; if your ALT normalizes, ask your clinician to document it.
Sleep apnea: the AHI (apnea-hypopnea index) improves substantially with 10–15% weight loss. A repeat sleep study at 12 months often reveals that CPAP settings can come down or, occasionally, that CPAP is no longer needed.
Blood pressure: the most immediate metabolic win, often within 4 weeks. Home BP logs beat clinic snapshots.
What to ask for at your next visit
A baseline: A1c, lipid panel, comprehensive metabolic panel (ALT, AST, glucose, creatinine), FIB-4 (calculable from the CMP + a CBC), waist circumference, and a home BP log for two weeks.
Repeats at month 3 and month 12. Anything abnormal at baseline that trended into normal range is a durable improvement — write it down; your future self and future clinicians will use it.
The trap: stopping the drug the moment weight is 'good enough'
Most patients who stop a GLP-1 within 12 months regain most of the weight — and, more importantly, most of the metabolic gains. Talk to your clinician about long-term dose strategy: a lower maintenance dose after the loss phase is a common pattern, not a full stop.
Frequently asked questions
- Do GLP-1s improve fatty liver disease?
- Yes — semaglutide has trial evidence for improving steatosis and inflammation in MASLD/MASH. Ask your clinician to track ALT/AST and a FIB-4 score before, during, and after treatment.
- Can sleep apnea resolve with GLP-1-driven weight loss?
- Often, yes, particularly with 10–15% weight loss. A repeat sleep study is the way to confirm; do not assume CPAP is still needed at the same settings.
- Does GLP-1 therapy reduce cardiovascular risk on its own?
- There is trial evidence for reduced MACE (major adverse cardiovascular events) with semaglutide in patients with established cardiovascular disease and overweight/obesity. Combined with BP and lipid management, the risk reduction is meaningful.
- How long should I stay on a GLP-1?
- Long-term therapy is the current working assumption for most patients, similar to blood pressure or cholesterol medications. Dose can often be reduced after the initial loss phase; complete discontinuation usually leads to regain.